AU2018448511B2 - Methods of treating diabetes in severe insulin-resistant diabetic subjects - Google Patents

Methods of treating diabetes in severe insulin-resistant diabetic subjects Download PDF

Info

Publication number
AU2018448511B2
AU2018448511B2 AU2018448511A AU2018448511A AU2018448511B2 AU 2018448511 B2 AU2018448511 B2 AU 2018448511B2 AU 2018448511 A AU2018448511 A AU 2018448511A AU 2018448511 A AU2018448511 A AU 2018448511A AU 2018448511 B2 AU2018448511 B2 AU 2018448511B2
Authority
AU
Australia
Prior art keywords
subject
test material
glucose
prodrug
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018448511A
Other languages
English (en)
Other versions
AU2018448511A1 (en
Inventor
Helena Edlund
Björn Eriksson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Betagenon AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon AB filed Critical Betagenon AB
Publication of AU2018448511A1 publication Critical patent/AU2018448511A1/en
Assigned to BETAGENON AB reassignment BETAGENON AB Amend patent request/document other than specification (104) Assignors: BALTICGRUPPEN BIO AB
Application granted granted Critical
Publication of AU2018448511B2 publication Critical patent/AU2018448511B2/en
Priority to AU2025238101A priority Critical patent/AU2025238101A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018448511A 2018-11-05 2018-11-05 Methods of treating diabetes in severe insulin-resistant diabetic subjects Active AU2018448511B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025238101A AU2025238101A1 (en) 2018-11-05 2025-09-26 Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2018/053203 WO2020095010A1 (en) 2018-11-05 2018-11-05 Methods of treating diabetes in severe insulin-resistant diabetic subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025238101A Division AU2025238101A1 (en) 2018-11-05 2025-09-26 Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects

Publications (2)

Publication Number Publication Date
AU2018448511A1 AU2018448511A1 (en) 2021-05-27
AU2018448511B2 true AU2018448511B2 (en) 2025-07-03

Family

ID=64332106

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018448511A Active AU2018448511B2 (en) 2018-11-05 2018-11-05 Methods of treating diabetes in severe insulin-resistant diabetic subjects
AU2025238101A Pending AU2025238101A1 (en) 2018-11-05 2025-09-26 Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025238101A Pending AU2025238101A1 (en) 2018-11-05 2025-09-26 Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects

Country Status (5)

Country Link
US (1) US20220023269A1 (https=)
JP (2) JP7432598B2 (https=)
AU (2) AU2018448511B2 (https=)
CA (1) CA3118629A1 (https=)
WO (1) WO2020095010A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910092D0 (en) * 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
CN113117241B (zh) * 2021-04-15 2022-01-28 中国科学院合肥物质科学研究院 一种提高胰岛素水平和敏感性的磁场发生装置及其应用
WO2025017194A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004162A2 (en) * 2009-07-08 2011-01-13 Betagenon Ab Compounds useful as medicaments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
JP2007517025A (ja) 2003-12-30 2007-06-28 エムディー バイオアルファ カンパニー リミテッド 代謝活性を上昇させるタンシノン誘導体を用いる、肥満およびメタボリックシンドロームの治療
EP2352374B1 (en) * 2008-10-29 2014-09-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MY182801A (en) 2013-09-26 2021-02-05 Energenesis Biomedical Co Ltd Compound for activating ampk and uses thereof
KR101986983B1 (ko) 2015-01-07 2019-06-07 창저우 더저 메디컬 사이언스 컴퍼니.,리미티드 망기페린-6-ｏ-베르베린염 수화물 및 그 제조방법과 용도
CN108473408B (zh) * 2016-01-05 2021-08-17 星野达雄 壳二孢氯素衍生物及其作为ampk激活剂的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004162A2 (en) * 2009-07-08 2011-01-13 Betagenon Ab Compounds useful as medicaments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PÄR STENEBERG ET AL: "PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients", JCI INSIGHT, vol. 3, no. 12, 21 June 2018 *
SIMON A. HAWLEY ET AL: "The Na + /Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels", DIABETES, vol. 65(9), 5 July 2016, pages 2784-2794 *

Also Published As

Publication number Publication date
JP7755618B2 (ja) 2025-10-16
US20220023269A1 (en) 2022-01-27
JP2022517483A (ja) 2022-03-09
WO2020095010A1 (en) 2020-05-14
CA3118629A1 (en) 2020-05-14
AU2025238101A1 (en) 2025-11-13
JP2023116697A (ja) 2023-08-22
JP7432598B2 (ja) 2024-02-16
AU2018448511A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
AU2018448511B2 (en) Methods of treating diabetes in severe insulin-resistant diabetic subjects
US9421208B2 (en) Methods for the treatment of solid tumors
ES2433476T3 (es) Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
EP1572196B1 (en) Combination of a dpp-iv inhibitor and a ppar-alpha compound
US9061012B2 (en) Uses of DGAT1 inhibitors
CA2794798C (en) Treatment of gout
AU2018392987A1 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
CN102026641A (zh) 并用或组合dpp-iv抑制剂和其它糖尿病治疗药的药品
PT2135603E (pt) Composições e métodos para aumentar a sensibilidade à insulina
AU2018392985A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN106963761A (zh) 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物
JP2019089825A (ja) 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
Weng et al. PER2 regulates reactive oxygen species production in the circadian susceptibility to ischemia/reperfusion injury in the heart
TW201022238A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
CN113271949A (zh) 用于治疗骨关节炎的西地那非
JP2009532498A (ja) 有機化合物の組合せ
JP2002536325A (ja) 疾患を治療するためのｌ−アルギニン基盤の処方およびその使用方法
US20100056460A1 (en) Combination of organic compounds
US20240398808A1 (en) Dihydrofolate for hypoglycemic activity
JP2020143037A (ja) 糖尿病合併心不全の治療用医薬組成物
Uğurlu et al. Pulmonary hypertension due to lithium therapy: a case report
EP4415711A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
JPH10504567A (ja) 急性腎不全の治療用医薬の製造のためのザプリナストの使用
TW200418450A (en) Combination of antidiabetic drugs
Wu Ankyrin-B and Mtor Complex 1 In The Regulation of Electrical Activities In The Heart

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BETAGENON AB

Free format text: FORMER NAME(S): BALTICGRUPPEN BIO AB

FGA Letters patent sealed or granted (standard patent)